C
Corey C. Ford
Researcher at University of New Mexico
Publications - 51
Citations - 7929
Corey C. Ford is an academic researcher from University of New Mexico. The author has contributed to research in topics: Glatiramer acetate & Multiple sclerosis. The author has an hindex of 28, co-authored 49 publications receiving 7416 citations. Previous affiliations of Corey C. Ford include University of Maryland, Baltimore.
Papers
More filters
Journal ArticleDOI
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis Results of a phase III multicenter, double‐blind, placebo‐controlled trial
Kenneth P. Johnson,Benjamin Rix Brooks,Jeffrey A. Cohen,Corey C. Ford,Jonathan Goldstein,Robert P. Lisak,Lawrence W. Myers,H. S. Panitch,John W. Rose,R. B. Schiffer,Timothy Vollmer,L. P. Weiner,Jerry S. Wolinsky +12 more
TL;DR: It is demonstrated that copolymer 1 treatment can significantly and beneficially alter the course of relapsing-remitting multiple sclerosis in a well-tolerated fashion.
Journal ArticleDOI
A Baseline for the Multivariate Comparison of Resting-State Networks
Elena A. Allen,Erik B. Erhardt,Eswar Damaraju,William Gruner,William Gruner,Judith M. Segall,Judith M. Segall,Rogers F. Silva,Rogers F. Silva,Martin Havlicek,Martin Havlicek,Srinivas Rachakonda,Jill Fries,Ravi Kalyanam,Ravi Kalyanam,Andrew M. Michael,Arvind Caprihan,Jessica A. Turner,Jessica A. Turner,Tom Eichele,Steven Adelsheim,Angela D. Bryan,Angela D. Bryan,Juan R. Bustillo,Vincent P. Clark,Vincent P. Clark,Sarah W. Feldstein Ewing,Francesca M. Filbey,Francesca M. Filbey,Corey C. Ford,Kent E. Hutchison,Kent E. Hutchison,Rex E. Jung,Rex E. Jung,Kent A. Kiehl,Kent A. Kiehl,Piyadasa W. Kodituwakku,Yuko M. Komesu,Andrew R. Mayer,Andrew R. Mayer,Godfrey D. Pearlson,John P. Phillips,John P. Phillips,Joseph Sadek,Michael Stevens,Ursina Teuscher,Ursina Teuscher,Robert J. Thoma,Vince D. Calhoun +48 more
TL;DR: A multivariate analytic approach that optimizes sensitivity and reduces unnecessary testing is introduced and is demonstrated by identifying the effects of age and gender on the resting-state networks of 603 healthy adolescents and adults.
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis : results of a phase III multicenter, double-blind, placebo-controlled trial
Kenneth P. Johnson,Benjamin Rix Brooks,Jeffrey A. Cohen,Corey C. Ford,Jonathan Goldstein,Robert P. Lisak,Lawrence W. Myers,H. S. Panitch,John W. Rose,R. B. Schiffer,Timothy Vollmer,L. P. Weiner,Jerry S. Wolinsky +12 more
TL;DR: Copolymer 1 (Copaxone) was studied in a multicenter (11-university) phase III trial of patients with relapsing-remitting multiple sclerosis and significantly more patients receiving copolym 1 were found to have improved and more receiving placebo worsened.
Journal ArticleDOI
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
Kenneth P. Johnson,Benjamin Rix Brooks,Jeffrey A. Cohen,Corey C. Ford,Jonathan Goldstein,R. P. Lisak,Lawrence W. Myers,Hillel Panitch,J. W. Rose,R. B. Schiffer,Timothy Vollmer,Leslie P. Weiner,Jerry S. Wolinsky +12 more
TL;DR: The clinical benefit of glatiramer acetate for both the relapse rate and for neurologic disability was sustained at the end of the extension trial.
Journal ArticleDOI
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
Jerry S. Wolinsky,Ponnada A. Narayana,Paul O'Connor,P. K. Coyle,Corey C. Ford,Kenneth P. Johnson,Kenneth P. Johnson,Aaron Miller,Aaron Miller,Lillian Pardo,Shaul Kadosh,David Ladkani,Lorne F. Kastrukoff,Pierre Duquette,Mark S. Freedman,Marc Debouverie,Catherine Lubetski,Gilles Edan,E Roullet,Christian Confavreux,Alan J. Thompson,L D Blumhardt,L D Blumhardt,Stanley Hawkins,Thomas F. Scott,Daniel Wynn,Joanna Cooper,Stephen Thurston,Stanton B. Elias,Clyde E. Markowitz,David Mattson,John H. Noseworthy,Elizabeth A. Shuster,Jonathan L. Carter,Fred D. Lublin,WH Stuart,Michael D. Kaufman,Gary Birnbaum,Kottil Rammohan,Ruth H. Whitham,Cornelia Mihai,Steven J. Greenberg,Craig M. Smith,Mark A. Agius,Stan Van Den Noort,Lawrence W. Myers,James G. Nelson,Douglas S. Goodin,Barry G. W. Arnason,Khurram Bashir,Sharon G. Lynch,Patricia K. Coyle,Stephen Kamin,William A. Sheremata,Galen Mitchell,Andrew D. Goodman,Norman J Kachuck,Peter B. Dunne,J. William Lindsey,Elliot M. Frohman,James D. Bowen,Benjamin Rix Brooks,John W. Rose,Harold L. Moses,Douglas Jeffrey,Anne H. Cross,Robert P. Lisak,Timothy Vollmer,Jack P. Antel,Gary Cutter,Luanne M. Metz,Henry F. McFarland,Steven Reingold,Fred D. Lublin,Irina Vainrub,Lucie Lambert,Fengwei Zhong,Jeff Rasmituth,Saria Momin,Rivka Kreitman,Galia Shifroni,Irit Pinchasi,Yafit Stark +82 more
TL;DR: To determine whether glatiramer acetate slows accumulation of disability in primary progressive multiple sclerosis, a new drug is developed that acts as a ‘spatially aggregating agent’ to reduce the risk of disease progression.